|
FR2160326B1
(2)
|
1971-11-19 |
1975-02-07 |
Anvar |
|
|
US4079127A
(en)
*
|
1976-10-28 |
1978-03-14 |
Board Of Regents Of The University Of Texas |
Thymosin alpha 1
|
|
US4116951A
(en)
|
1977-04-22 |
1978-09-26 |
Hoffmann-La Roche Inc. |
[Asn2 ]-thymosin α1 and analogs thereof
|
|
US4148788A
(en)
*
|
1978-01-23 |
1979-04-10 |
Hoffmann-La Roche Inc. |
Synthesis of thymosin α1
|
|
US4690623A
(en)
*
|
1978-05-31 |
1987-09-01 |
Karl Eickmann |
Fluid pumps, fluid motors and devices, which include a coned ring
|
|
DE2919592A1
(de)
|
1979-05-15 |
1981-01-15 |
Max Planck Gesellschaft |
Verfahren zur herstellung von thymosin- alpha 1 und derivaten davon
|
|
US4470926A
(en)
|
1980-01-18 |
1984-09-11 |
Max-Planck-Gesellschaft zur F/o/ rderung der Wissenschaften e.V. |
Medicaments containing thymosin alpha 1 fragments and having an immunostimulant action, and fragments of thymosin alpha 1
|
|
DE3100974A1
(de)
|
1980-01-18 |
1982-01-21 |
Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V., 3400 Göttingen |
Thymosin(alpha)(pfeil abwaerts)1(pfeil abwaerts)-fragmente enthaltende arzneimittel mit immunregulierender wirkung, und thymosin(alpha)(pfeil abwaerts)1(pfeil abwaerts)-fragmente
|
|
US4612365A
(en)
|
1980-03-25 |
1986-09-16 |
Max-Planck-Gesellschaft Zur Foederung Der Wissenschaften |
Medicaments containing alpha 1-thymosin and having an immuno regulatory action and alpha 1-thymosin fragments
|
|
US4293455A
(en)
*
|
1980-04-07 |
1981-10-06 |
Rockefeller University |
N.sup.α -Desacetylthymosinα1 and process
|
|
GR74132B
(2)
|
1980-05-22 |
1984-06-06 |
Deutsches Krebsforsch |
|
|
US4390623A
(en)
|
1980-10-02 |
1983-06-28 |
Hooper Trading Company |
Serum-free and mitogen-free T-cell growth factor and process for making same
|
|
US4475196A
(en)
|
1981-03-06 |
1984-10-02 |
Zor Clair G |
Instrument for locating faults in aircraft passenger reading light and attendant call control system
|
|
US4464355A
(en)
*
|
1981-03-26 |
1984-08-07 |
Hooper Trading Co. |
Serum-free and mitogen-free T-cell growth factor and process for making same
|
|
US4448879A
(en)
*
|
1981-03-26 |
1984-05-15 |
Hooper Trading Company |
High yield process for in vitro production of serum-free and mitogen-free interleukin-2
|
|
US4447233A
(en)
|
1981-04-10 |
1984-05-08 |
Parker-Hannifin Corporation |
Medication infusion pump
|
|
US4406830A
(en)
*
|
1981-04-17 |
1983-09-27 |
Shanksville Corporation, N.V. |
Regulatory glycoprotein for immune response and the use thereof in the production of T-cell growth factor
|
|
DE3120912A1
(de)
|
1981-05-26 |
1982-12-16 |
Hoechst Ag, 6000 Frankfurt |
Verfahren zur herstellung von p-nitrophenetol
|
|
US4439196A
(en)
|
1982-03-18 |
1984-03-27 |
Merck & Co., Inc. |
Osmotic drug delivery system
|
|
US4447224A
(en)
|
1982-09-20 |
1984-05-08 |
Infusaid Corporation |
Variable flow implantable infusion apparatus
|
|
US4487603A
(en)
|
1982-11-26 |
1984-12-11 |
Cordis Corporation |
Implantable microinfusion pump system
|
|
US4504415A
(en)
*
|
1983-04-04 |
1985-03-12 |
Hoffman-La Roche Inc. |
Synthesis of thymosin α1 and desacetyl thymosin α1
|
|
US4486194A
(en)
|
1983-06-08 |
1984-12-04 |
James Ferrara |
Therapeutic device for administering medicaments through the skin
|
|
US4614731A
(en)
*
|
1983-09-15 |
1986-09-30 |
Hoffmann-La Roche Inc. |
Peptide having immunopotentiating activity similar to thymosin alpha1
|
|
US4659694A
(en)
*
|
1983-10-27 |
1987-04-21 |
Hoffmann-La Roche Inc. |
Prothymosin alpha
|
|
US4716148A
(en)
*
|
1984-08-13 |
1987-12-29 |
Hoffman-La Roche Inc. |
Prothymosin alpha
|
|
US5503841A
(en)
|
1985-09-20 |
1996-04-02 |
Cetus Oncology Corporation |
Human IL-2 as a vaccine adjuvant
|
|
US5100664A
(en)
|
1985-09-20 |
1992-03-31 |
Cetus Corporation |
Human IL-2 as a vaccine adjuvant
|
|
US5643565A
(en)
|
1985-09-20 |
1997-07-01 |
Chiron Corporation |
Human IL-2 as a vaccine adjuvant
|
|
US5098702A
(en)
*
|
1986-04-09 |
1992-03-24 |
Cetus Corporation |
Combination therapy using interleukin-2 and tumor necrosis factor
|
|
EP0271521A4
(en)
|
1986-05-09 |
1989-11-14 |
Sloan Kettering Inst Cancer |
Lipopolysaccharide and natural factor compositions for anti-tumor therapy and method of treatment.
|
|
US4959217A
(en)
|
1986-05-22 |
1990-09-25 |
Syntex (U.S.A.) Inc. |
Delayed/sustained release of macromolecules
|
|
US4925678A
(en)
|
1987-04-01 |
1990-05-15 |
Ranney David F |
Endothelial envelopment drug carriers
|
|
US5080646A
(en)
|
1988-10-03 |
1992-01-14 |
Alza Corporation |
Membrane for electrotransport transdermal drug delivery
|
|
US5376369A
(en)
|
1987-11-03 |
1994-12-27 |
Syntex (U.S.A.) Inc. |
Vaccine adjuvant
|
|
SE8801426D0
(sv)
|
1988-04-15 |
1988-04-15 |
Ulf Rothman |
Forfarande och medel for blodbehandling
|
|
ATE147633T1
(de)
*
|
1988-10-27 |
1997-02-15 |
Univ Minnesota |
Immunhilfsmittel aus liposome enthaltend lymphokin il -2
|
|
CA2003455C
(en)
*
|
1988-11-23 |
2000-02-22 |
Craig B. Thompson |
Immunotherapy involving cd28 stimulation
|
|
US6534055B1
(en)
*
|
1988-11-23 |
2003-03-18 |
Genetics Institute, Inc. |
Methods for selectively stimulating proliferation of T cells
|
|
US5167616A
(en)
|
1989-12-14 |
1992-12-01 |
Alza Corporation |
Iontophoretic delivery method
|
|
IT1238231B
(it)
|
1989-12-18 |
1993-07-12 |
Consiglio Nazionale Ricerche |
Impiego di immunomodulanti come agenti sinergici di chemioterapici nella terapia dei tumori
|
|
US5830452A
(en)
*
|
1990-11-20 |
1998-11-03 |
Chiron Corporation |
Method for enhancing the anti-tumor therapeutic index of interleukin-2
|
|
US5225182A
(en)
|
1991-10-31 |
1993-07-06 |
Sharma Yash P |
Vectored drug delivery system using a cephaloplastin linking agent and a methed of using the system
|
|
DE69324671D1
(de)
|
1992-02-10 |
1999-06-02 |
Interferon Sciences Inc |
Verbesserte alpha-interferon-zusammensetzung und verfahren zu ihrer herstellung aus leukocyten des menschlichen peripheren blute
|
|
AU4662393A
(en)
|
1992-07-08 |
1994-01-31 |
Schering Corporation |
Use of gm-csf as a vaccine adjuvant
|
|
CN1094310A
(zh)
|
1992-12-15 |
1994-11-02 |
托马斯·C·梅里根 |
人体免疫缺陷性病毒感染用组合式化学疗法
|
|
US5747024A
(en)
|
1993-03-08 |
1998-05-05 |
Immunex Corporation |
Vaccine adjuvant comprising interleukin-15
|
|
ATE293686T1
(de)
|
1993-06-04 |
2005-05-15 |
Us Navy |
Verfahren zur selektiven stimulierung der t- zellproliferation.
|
|
ES2245778T3
(es)
*
|
1993-08-11 |
2006-01-16 |
Jenner Technologies |
Vacuna contra el cancer de prostata.
|
|
CN1044781C
(zh)
|
1994-02-05 |
1999-08-25 |
丹东市生物制品免疫技术应用研究中心 |
复方免疫抗生素
|
|
DE4412794A1
(de)
*
|
1994-04-14 |
1995-12-14 |
Univ Ludwigs Albert |
Verfahren zur Herstellung von dendritischen Zellen, so erhaltene Zellen und Behälter zur Durchführung dieses Verfahrens
|
|
US5632983A
(en)
*
|
1994-11-17 |
1997-05-27 |
University Of South Florida |
Method for treating secondary immunodeficiency
|
|
EP0789588B1
(en)
|
1994-11-17 |
2005-01-19 |
University Of South Florida |
Method for making a medicament for treating secondary immunodeficiency
|
|
US5626838A
(en)
*
|
1995-03-13 |
1997-05-06 |
The Procter & Gamble Company |
Use of ketorolac for treatment of squamous cell carcinomas of the oral cavity or oropharynx
|
|
WO1996034956A1
(en)
|
1995-05-04 |
1996-11-07 |
United States Of America, Represented By The Secretary Of The Navy |
Methods for modulating t cell survival by modulating bcl-xl protein level
|
|
US5788963A
(en)
*
|
1995-07-31 |
1998-08-04 |
Pacific Northwest Cancer Foundation |
Isolation and/or preservation of dendritic cells for prostate cancer immunotherapy
|
|
NZ331369A
(en)
|
1996-02-21 |
2001-04-27 |
Franco Lori |
Use of a genetic construct that directs virus expression in a lymphoid organ or a transduced cell thereof for genetic immunization
|
|
US5849589A
(en)
*
|
1996-03-11 |
1998-12-15 |
Duke University |
Culturing monocytes with IL-4, TNF-α and GM-CSF TO induce differentiation to dendric cells
|
|
US6017527A
(en)
*
|
1996-07-10 |
2000-01-25 |
Immunex Corporation |
Activated dendritic cells and methods for their activation
|
|
US5849307A
(en)
|
1997-03-26 |
1998-12-15 |
The Picower Institute For Medical Research |
Vaccine adjuvant
|
|
US6358508B1
(en)
*
|
1997-06-11 |
2002-03-19 |
Human Genome Sciences, Inc. |
Antibodies to human tumor necrosis factor receptor TR9
|
|
WO1999020788A1
(en)
|
1997-10-17 |
1999-04-29 |
University Of South Florida |
Method to diagnose and monitor cellular immune deficiencies
|
|
DE69840739D1
(de)
*
|
1997-10-27 |
2009-05-28 |
Merix Bioscience Inc |
Methode und Zusammensetzung zur Herstellung von reifen dendritischen Zellen
|
|
JP2002502884A
(ja)
*
|
1998-02-12 |
2002-01-29 |
アメリカン・サイアナミド・カンパニー |
インターロイキン−１２および単純ヘルペスウイルス抗原を含んでなるワクチン
|
|
US20050124645A1
(en)
*
|
1998-04-20 |
2005-06-09 |
Finkel Terri H. |
Methods and compositions for increasing CD4lymphocyte immune responsiveness
|
|
EP0974357A1
(en)
|
1998-07-16 |
2000-01-26 |
Schering-Plough |
Chemokines as adjuvants of immune response
|
|
IL125608A0
(en)
|
1998-07-30 |
1999-03-12 |
Yeda Res & Dev |
Tumor associated antigen peptides and use of same as anti-tumor vaccines
|
|
GB9827103D0
(en)
|
1998-12-10 |
1999-02-03 |
Onyvax Ltd |
New cancer treatments
|
|
US6017537A
(en)
|
1998-12-18 |
2000-01-25 |
Connaught Laboratories, Inc. |
Formyl methionyl peptide vaccine adjuvant
|
|
US6350589B1
(en)
*
|
1998-12-31 |
2002-02-26 |
Viragen, Inc. |
Compositions of highly-purified natural mixtures of type I interferon derived from leukocytes and methods
|
|
GB9903664D0
(en)
*
|
1999-02-17 |
1999-04-14 |
Isis Innovation |
Adjuvant and cell maturation agent
|
|
US6667175B1
(en)
|
1999-06-15 |
2003-12-23 |
The Trustees Of Columbia University |
Generation of antigen specific T suppressor cells for treatment of rejection
|
|
US7056503B2
(en)
*
|
1999-08-19 |
2006-06-06 |
Regents Of The University Of Michigan |
Enclosures housing cell-coated supports for treating tumors
|
|
US6406699B1
(en)
|
1999-10-05 |
2002-06-18 |
Gary W. Wood |
Composition and method of cancer antigen immunotherapy
|
|
KR20030032922A
(ko)
*
|
2000-02-24 |
2003-04-26 |
싸이트 테라피스 인코포레이티드 |
세포의 동시 자극 및 농축
|
|
AU2001270031B2
(en)
*
|
2000-06-22 |
2005-11-03 |
Wyeth Holdings Corporation |
QS-21 and IL-12 as an adjuvant combination
|
|
US7182942B2
(en)
|
2000-10-27 |
2007-02-27 |
Irx Therapeutics, Inc. |
Vaccine immunotherapy for immune suppressed patients
|
|
US20060194242A1
(en)
*
|
2000-10-27 |
2006-08-31 |
Hadden John W |
Immunotherapy for immune suppressed patients
|
|
US20070031372A1
(en)
*
|
2004-08-05 |
2007-02-08 |
Hadden John W |
Vaccine immunotherapy for immune suppressed patients
|
|
US20070154399A1
(en)
*
|
2000-10-27 |
2007-07-05 |
Hadden John W |
Immunotherapy for immune suppressed patients
|
|
AU2002232560A1
(en)
|
2000-10-27 |
2002-05-06 |
Immuno-Rx, Inc |
Vaccine immunotherapy for immune suppressed patients
|
|
US20070025958A1
(en)
*
|
2000-10-27 |
2007-02-01 |
Hadden John W |
Vaccine immunotherapy
|
|
FR2823222B1
(fr)
|
2001-04-06 |
2004-02-06 |
Merial Sas |
Vaccin contre le virus de la fievre du nil
|
|
AU2002342151B2
(en)
*
|
2001-10-26 |
2007-07-19 |
Immuno-Rx, Inc. |
Immunotherapy for reversing immune suppression
|
|
DE10154579A1
(de)
*
|
2001-11-07 |
2003-05-28 |
Medigene Ag |
Topikale Verwendung von Cytokinen und Chemokinen zur Behandlung von viralen oder mykotischen Hauterkrankungen oder Tumorerkrankungen
|
|
CA2472578A1
(en)
|
2002-01-24 |
2003-07-31 |
Yissum Research Development Company Of The Hebrew University Of Jerusalem |
Anti-cancer combination and use thereof
|
|
WO2004056977A1
(en)
|
2002-12-13 |
2004-07-08 |
Aventis Pasteur, Inc. |
Production of alvac on avian embryonic stem cells
|
|
GEP20084487B
(en)
*
|
2002-12-26 |
2008-09-25 |
Mountain View Pharmaceuticals |
Polymer conjugates of cytokines, chemokines, growth factors, polypeptide hormones and antagonists thereof
|
|
WO2004092212A2
(en)
|
2003-04-15 |
2004-10-28 |
Sanofi Pasteur Limited |
Tumor antigens bfa5 for prevention and/or treatment of cancer
|
|
US6896879B2
(en)
*
|
2003-07-03 |
2005-05-24 |
Cel-Sci Corporation |
Method of pre-sensitizing cancer prior to treatment with radiation and/or chemotherapy and a novel cytokine mixture
|
|
US20070196335A1
(en)
|
2004-02-09 |
2007-08-23 |
The Johns Hopkins University |
Immune Modulation By Regulating Expression Of The "Minor" Gene In Immune Dendritic Cells
|
|
GB0409799D0
(en)
*
|
2004-04-30 |
2004-06-09 |
Isis Innovation |
Method of generating improved immune response
|
|
CN101005760A
(zh)
|
2004-06-04 |
2007-07-25 |
塞尔-赛公司 |
改变cd4/cd8和进入肿瘤的单核细胞浸润液的方法
|
|
WO2005123120A1
(en)
|
2004-06-16 |
2005-12-29 |
Smart Drug Systems Inc. |
Sustained release vaccine composition
|
|
JP5623004B2
(ja)
|
2004-10-25 |
2014-11-12 |
ベイラー リサーチ インスティテュートＢａｙｌｏｒ Ｒｅｓｅａｒｃｈ Ｉｎｓｔｉｔｕｔｅ |
熱ショックをかけたメラノーマ細胞体が装填された樹状細胞
|
|
US20070065415A1
(en)
|
2005-09-16 |
2007-03-22 |
Kleinsek Donald A |
Compositions and methods for the augmentation and repair of defects in tissue
|
|
CA2663749A1
(en)
|
2005-09-21 |
2007-03-29 |
Dask Technologies, Llc |
Methods and compositions for organ and tissue functionality
|
|
KR20220113543A
(ko)
|
2005-12-08 |
2022-08-12 |
노쓰웨스트 바이오써라퓨틱스, 인크. |
미성숙 단핵구성 수지상 세포의 활성화를 유도하기 위한 조성물 및 방법
|
|
EP2013333A2
(en)
|
2006-05-04 |
2009-01-14 |
GE Healthcare Bio-Sciences AB |
Separation of cells
|
|
US20090181078A1
(en)
*
|
2006-09-26 |
2009-07-16 |
Infectious Disease Research Institute |
Vaccine composition containing synthetic adjuvant
|
|
JP5331100B2
(ja)
|
2007-04-25 |
2013-10-30 |
イミュアールエックス・インコーポレーテッド |
Ｎｋｔアクチベータ、ｃｄ４０アゴニスト、及び任意選択的に抗原を含んでなるアジュバント組合せと、細胞性免疫において相乗的な増強を誘導するためのその使用
|
|
AU2008279550B2
(en)
*
|
2007-06-21 |
2012-08-09 |
Angelica Therapeutics, Inc. |
Modified toxins
|
|
JP5563472B2
(ja)
*
|
2007-11-28 |
2014-07-30 |
アイ アール エックス セーラピューティクス， インコーポレイテッド |
免疫学的効果を増大させる方法
|
|
CA2758834C
(en)
|
2008-04-14 |
2017-11-07 |
Irx Therapeutics, Inc. |
Primary cell derived biologic modified manufacturing process
|
|
MX2010012985A
(es)
|
2008-05-29 |
2011-02-15 |
Irx Therapeutics Inc |
Mecanismo de accion de la sustancia biologica derivada de celula primaria.
|
|
CA3017298C
(en)
*
|
2009-05-15 |
2021-09-28 |
Irx Therapeutics, Inc. |
Compositions comprising primary cell-derived biologics for enhancing immune responses in patients
|
|
ES2667476T3
(es)
*
|
2009-12-08 |
2018-05-11 |
Irx Therapeutics, Inc. |
Método para invertir la supresión inmunitaria de células de Langerhans
|
|
WO2012037551A2
(en)
|
2010-09-17 |
2012-03-22 |
Irx Therapeutics, Inc. |
Primary cell-derived biologic and wt1 synthetic long peptide vaccine
|